5.1. Data Source
This immunogenicity analysis was based on samples obtained from subjects enrolled in the first comprehensive phase 3 clinical program for DAXI, which was for the treatment of glabellar lines. This program consisted of two identically designed double-blind, placebo-controlled, single-dose studies (SAKURA 1 [